Fenofibrate Use in Chronic Kidney Disease

Introduction to Fenofibrate Recommendations

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that fibric acid derivatives, such as fenofibrate, should not be used to reduce cardiovascular risk in patients with chronic kidney disease (CKD) due to insufficient evidence of net clinical benefit and safety concerns 1, 2
The American Journal of Kidney Diseases suggests that fenofibrate may be considered exclusively for patients with markedly elevated triglycerides (>1000 mg/dL) to prevent acute pancreatitis, not for cardiovascular risk reduction, with mandatory dose adjustment based on kidney function 4, 5

For patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m², standard dosing of fenofibrate up to 160 mg daily may be used 4, 5
For patients with eGFR 30-59 mL/min/1.73 m², the dose should be started at 54 mg daily and increased only after evaluating renal function and lipid response 4, 5
Fenofibrate is contraindicated in patients with eGFR <30 mL/min/1.73 m² (CKD stages 4-5) and in dialysis patients 4, 5, 6

The National Kidney Foundation recommends against combining fenofibrate with statins in CKD patients due to increased risk of rhabdomyolysis and myopathy 6
For lipid management in CKD, statins (or statin/ezetimibe combinations) remain the evidence-based first-line therapy for cardiovascular risk reduction, with a Grade 1A recommendation for adults ≥50 years with eGFR <60 mL/min/1.73 m² 1, 2
Therapeutic lifestyle changes, such as dietary modification, weight reduction, increased physical activity, alcohol reduction, and glycemic control, should be prioritized for managing hypertriglyceridemia 1, 2, 3